Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the standard first-line treatment for most patients with hormone receptor (HR) positive, human epidermal growth factor receptor (HER2) negative advanced breast cancer. However, resistance to ET and CDK4/6i inevi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jun, Chan, Jack Junjie, Toh, Ching Han, Yap, Yoon-Sim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491615/
https://www.ncbi.nlm.nih.gov/pubmed/37684290
http://dx.doi.org/10.1038/s41523-023-00578-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491615/
https://www.ncbi.nlm.nih.gov/pubmed/37684290
http://dx.doi.org/10.1038/s41523-023-00578-3

Ejemplares similares